Anakinra for treating moderate asthma attacks
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether a drug called anakinra, given as a shot, can help treat moderate asthma attacks right when they happen, reducing the need for other rescue treatments. It may help people whose asthma is not well controlled and who have needed steroids in the past year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a doctor's diagnosis of persistent asthma and take a daily controller inhaler (like a steroid or combination inhaler).
- You must have had an asthma attack that required oral steroids (like prednisone) in the past year.
- You cannot have other chronic lung diseases (like COPD, cystic fibrosis, or emphysema).
- You must not have had a breathing tube placed for asthma in the last year, and you must not be a current or heavy smoker.
- You need to be willing to give informed consent and be able to self-inject the study medication (anakinra or placebo) at home.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called anakinra that may reduce heart swelling in children with a severe heart condition called acute myocarditis. It might help their heart recover faster while they are in the intensive care unit.
This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.
This trial tests an anti-inflammatory drug (anakinra) in people whose inner-ear hearing problems have not improved with steroid treatment. It aims to reduce worsening hearing caused by autoimmune inner ear disease or difficult-to-control Meniere’s disease.
This trial tests different doses and ways of giving a medicine called anakinra to preterm babies. It aims to find the safest and most effective dose to help reduce inflammation.
This early-phase trial tests a biologic medicine (anakinra) given after an ACL injury to try to prevent or reduce later osteoarthritis (wear-and-tear arthritis). It enrolls young adults who recently tore their ACL and are planning a specific type of ACL reconstruction.
This trial tests if taking anakinra (a targeted medicine) only when you have a painful FMF attack can help, instead of taking it every day. It is for people with Familial Mediterranean Fever (FMF) whose attacks continue despite taking colchicine, and who do not want daily injections.
Hear when a new Asthma (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.